13-cyclopent-2-enyl-tridecanoic acid | 502-30-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 13-cyclopent-2-enyl-tridecanoic acid
• 英文别名: chaulmoogric acid；(+/-)-1-(cyclopenten-(2)-yl)-tridecanoic acid-(13)；(+/-)-1-(Cyclopenten-(2)-yl)-tridecansaeure-(13)；13-Cyclopent-2-enyl-tridecansaeure；Chaulmoograsaeure；Chaulmoogrylsaeure；13-(Cyclopent-2-enyl)tridecanoic acid；13-cyclopent-2-en-1-yltridecanoic acid
• CAS: 502-30-7
• 化学式: C₁₈H₃₂O₂
• 分子量: 280.451
• InChiKey: XMVQWNRDPAAMJB-UHFFFAOYSA-N

物化性质

• 熔点：
  68.5 °C
• 沸点：
  408.2±14.0 °C(Predicted)
• 密度：
  0.948±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  20
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  13-cyclopent-2-enyl-tridecanoic acid 在 乙醇 、 氢溴酸 、 溶剂黄146 、 锌 作用下， 生成 13-cyclopentyl-tridecanoic acid
  参考文献：
  名称：

  Power; Gornall, Journal of the Chemical Society, 1904, vol. 85, p. 856

  摘要：

  DOI：
• 作为产物：
  描述：

  13-cyclopent-2-enyl-12-oxo-tridecanenitrile 在 氢氧化钾 、 sodium ethanolate 作用下， 生成 13-cyclopent-2-enyl-tridecanoic acid
  参考文献：
  名称：

  Perkins; Cruz, Journal of the American Chemical Society, 1927, vol. 49, p. 1073

  摘要：

  DOI：

文献信息

• GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS
  申请人：South Dakota Board of Regents

  公开号：US20200048305A1

  公开（公告）日：2020-02-13

  The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

  本发明描述了含有胆固醇-连接剂-谷胱甘肽共轭物的组合物，通过克服血脑屏障（BBB）进入中枢神经系统的屏障入口，包括这些组合物的胶束和脂质体形式。此外，还公开了通过给予这些组合物治疗受试者的方法。
• 包含奥利司他与GLP-1受体激动剂的组合物 及其用途
  申请人：中山万汉制药有限公司

  公开号：CN109010310B

  公开（公告）日：2019-05-24

  本发明属于医药技术领域，具体涉及一种包含奥利司他与GLP‑1受体激动剂的组合物及其用途。本发明提供的包含奥利司他与GLP‑1受体激动剂的组合物，包含奥利司他，以及包含GLP‑1受体激动剂与共聚物的纳米粒。本发明提供的包含奥利司他与GLP‑1受体激动剂的组合物可以实现奥利司他与GLP‑1受体激动剂的联合口服用药，生物利用度高，具有良好的抑制体重增加和减肥效果。
• [EN] ASYMMETRIC SYNTHESIS OF CHIRAL COMPOUNDS<br/>[FR] SYNTHÈSE ASYMÉTRIQUE DE COMPOSÉS CHIRAUX
  申请人：ISIS INNOVATION

  公开号：WO2015008097A1

  公开（公告）日：2015-01-22

  The present invention provides processes for the production of chiral compounds in a stereoisomeric excess, the processes comprising: (i) contacting a first compound comprising an alkene or alkyne bond with a hydrometallating agent, wherein the first compound and the hydrometallating agent are contacted under conditions such that the first compound is hydrometallated by said hydrometallating agent; and (ii) contacting the hydrometallated first compound with a second compound comprising an allylic group, wherein the hydrometallated first compound and the second compound are contacted under conditions such that they undergo an asymmetric allylic alkylation reaction in which a carbon atom of the hydrometallated first compound binds to a carbon atom of said allylic group, forming a stereoisomeric excess of a compound having a chiral centre in an allylic position, said chiral centre being located at the carbon atom bound by said first compound, wherein said asymmetric allylic alkylation reaction is performed in the presence of a metal catalyst comprising a chiral ligand. In particular, the present invention provides processes for the production of a stereoisomeric excess of a compound of the formula (IA), (IB), (IA') or (IB') as defined herein.

  本发明提供了用于在立体异构过剩中生产手性化合物的工艺，该工艺包括：（i）将包含烯烃或炔烃键的第一化合物与氢化金属试剂接触，其中第一化合物和氢化金属试剂在条件下接触，使得第一化合物被所述氢化金属试剂氢化；以及（ii）将氢化的第一化合物与包含烯丙基团的第二化合物接触，其中氢化的第一化合物和第二化合物在条件下接触，使它们经历不对称烯丙基烷基化反应，在该反应中，氢化的第一化合物的一个碳原子与所述烯丙基团的一个碳原子结合，形成具有手性中心的化合物的立体异构过剩，在所述手性中心位于所述第一化合物结合的碳原子处，其中所述不对称烯丙基烷基化反应在存在包含手性配体的金属催化剂的情况下进行。具体地，本发明提供了用于生产具有公式（IA）、（IB）、（IA'）或（IB'）的化合物的立体异构过剩的工艺。
• QUATERNIZED AMMONIUM SALTS OF HYDROCARBYL EPOXIDES AND USE THEREOF AS ADDITIVES IN FUELS AND LUBRICANTS
  申请人：BASF SE

  公开号：US20150266808A1

  公开（公告）日：2015-09-24

  The present invention relates to novel quaternized ammonium salts of hydrocarbyl epoxides, to the preparation thereof and to the use thereof as a fuel additive and lubricant additive, such as, more particularly, as a detergent additive; for reducing or preventing deposits in the injection systems of direct injection diesel engines, especially in common rail injection systems, for reducing the fuel consumption of direct injection diesel engines, especially of diesel engines with common rail injection systems, and for minimizing power loss in direct injection diesel engines, especially in diesel engines with common rail injection systems; and as an additive for gasoline fuels, especially for operation of DISI engines.

  本发明涉及新型烃氧化物的季铵盐，以及其制备和用作燃料添加剂和润滑剂添加剂的用途，特别是作为一种清洁剂添加剂；用于减少或预防直喷柴油发动机的喷射系统中的沉积物，在共轨喷射系统中尤其如此，用于减少直喷柴油发动机的燃油消耗，尤其是共轨喷射系统的柴油发动机，并用于最小化直喷柴油发动机的功率损失，尤其是在具有共轨喷射系统的柴油发动机中；以及作为汽油燃料的添加剂，特别是用于DISI发动机的运行。
• THERAPEUTIC HYPERBRANCHED POLYGLYCEROL ENCAPSULATED BIOMOLECULES
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160361425A1

  公开（公告）日：2016-12-15

  Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.

  本发明涉及改进口服、直肠或黏膜透传输的治疗生物分子（例如蛋白质）的方法，以及使用这些方法制备的组合物和将这些组合物用于治疗的方法。具体而言，本发明将治疗生物分子与高分支聚合物（HBPs）如高分支聚甘油（HPG）共轭。当这种共轭物被口服给予受试者时，HBP可以保护治疗生物分子免受胃酸环境和胃肠道的蛋白酶攻击，同时促进治疗生物分子在肠道更高的pH环境中的吸收。这些方法和组合物可用于改善给予受试者各种治疗生物分子的途径。